Cited by 503Advanced Glycation End Products researchImmune Response and InflammationImmunotherapy and Immune Responses

Release of High Mobility Group Box 1 by Dendritic Cells Controls T Cell Activation via the Receptor for Advanced Glycation End Products

Open access
Dumitriu, Ingrid E, Baruah, Paramita, Valentinis, Barbara, Voll, Reinhard E, Herrmann, Martin, Nawroth, Peter P, Arnold, Bernd, Bianchi, Marco E +2 more·2005·The Journal of Immunology

Abstract

High mobility group box 1 (HMGB1) is an abundant and conserved nuclear protein that is released by necrotic cells and acts in the extracellular environment as a primary proinflammatory signal. In this study we show that human dendritic cells, which are specialized in Ag presentation to T cells, actively release their own HMGB1 into the extracellular milieu upon activation. This secreted HMGB1 is necessary for the up-regulation of CD80, CD83, and CD86 surface markers of human dendritic cells and for IL-12 production. The HMGB1 secreted by dendritic cells is also required for the clonal expansion, survival, and functional polarization of naive T cells. Using neutralizing Abs and receptor for advanced glycation end product-deficient (RAGE−/−) cells, we demonstrate that RAGE is required for the effect of HMGB1 on dendritic cells. HMGB1/RAGE interaction results in downstream activation of MAPKs and NF-κB. The use of an ancient signal of necrosis, HMGB1, by dendritic cells to sustain their own maturation and for activation of T lymphocytes represents a profitable evolutionary mechanism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.174.12.7506

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Dumitriu, I. E., Baruah, P., Valentinis, B., Voll, R. E., Herrmann, M., Nawroth, P. P., Arnold, B., Bianchi, M. E., Manfredi, A. A., & Rovere-Querini, P.
Affiliations
  • IRCCS Ospedale San Raffaele (IT)
  • MolMed (Italy) (IT)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Department of Internal Medicine III, Institute for Clinical Immunology and Rheumatology, Friedrich Alexander University , Erlangen-Nuremberg ,
  • Heidelberg University (DE)
  • German Cancer Research Center (DE)
  • Vita-Salute San Raffaele University (IT)
  • Cancer Immunotherapy and Gene Therapy Program, Clinical Immunology Unit, H. San Raffaele Scientific Institute , Milan ,
Corresponding author
Baruah, Paramita
Venue
The Journal of Immunology
Published
2005-06
Volume
174
Issue
12
Pages
7506-7515
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2143998429
Cited by
503
References
46
Citations by year
2026: 2 · 2025: 7 · 2024: 11 · 2023: 12 · 2022: 24 · 2021: 16 · 2020: 22 · 2019: 16 · 2018: 19 · 2017: 30 · 2016: 29 · 2015: 32 · 2014: 29 · 2013: 39 · 2012: 29
FWCI
22.03
Type
journal article
Language
en
Open access
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
HMGB1, dendritic cells, RAGE, T cell activation, dendritic cell maturation, IL-12, CD80, CD83, CD86, T cell polarization, necrosis, MAPK signaling, NF-κB, extracellular HMGB1
MeSH terms
Receptor for Advanced Glycation End Products, Cell Differentiation, Cell Survival, Cells, Cultured, Clone Cells, Cytosol, Dendritic Cells, Extracellular Space, Growth Inhibitors, Humans, Immune Sera, Lymphocyte Activation, Receptors, Immunologic, CD4-Positive T-Lymphocytes, T-Lymphocyte Subsets, Resting Phase, Cell Cycle, NF-kappa B, Th1 Cells, Interleukin-12, Coculture Techniques, Active Transport, Cell Nucleus, HMGB1 Protein, Extracellular Signal-Regulated MAP Kinases, p38 Mitogen-Activated Protein Kinases, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review